As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, presented three posters during the American ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

For low-risk patients with papillary thyroid carcinoma interested in something other than surgery or surveillance, ...

Dry eye disease metrics, such as NIBUT and MG dropout, may serve as predictive biomarkers for possible thyroid disorders.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

From that, the PRAC has concluded that the data “does not support a causal association” between the drugs and thyroid cancer and sees no need to update the product information at this time.

These may include thyroid disease. Researchers are investigating ... Her clinical interests and expertise further include skin cancer prevention and overall skin wellness. A graduate of Wellesley ...

Autoimmune thyroid disease (AITD) causes cellular damage and alters thyroid gland function by humoral and cell-mediated mechanisms. Cellular damage occurs when sensitized T-lymphocytes and/or ...

It is designed to advance the understanding of thyroid disorders and thyroid cancer, and to offer guidance to physicians, nurses, pharmacists, and the entire patient care team.

Cancer metabolism refers to the alterations in cellular metabolism pathways that are evident in cancer cells compared with most normal tissue cells. Metabolic alterations in cancer cells are ...